Therapeutic potential of microRNAs in heart failure

Current Cardiology Reports

Volumn 12, Issue 3, 2010, Pages 209-215

  Dorn II, Gerald W ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Cardiac disease; Heart failure; MicroRNA; MRNA

Indexed keywords

MESSENGER RNA; MICRORNA; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; PARVOVIRUS VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG TARGETING; EXPERIMENTAL MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC MANIPULATION; HEART ASSIST DEVICE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE HYPERTROPHY; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; RNA INTERFERENCE; TRANSLATION REGULATION; VIRAL GENE DELIVERY SYSTEM;

CARDIOMEGALY; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; MICRORNAS; MYOCARDIUM; MYOCYTES, CARDIAC; RNA, MESSENGER;

EID: 77956394522     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0096-7     Document Type: Review

References (35)

1. Latronico MV, Condorelli G: MicroRNAs and cardiac pathology. Nat Rev Cardiol 2009, 6:419-429.
2. Standart N, Jackson RJ: MicroRNAs repress translation of m7Gppp-capped target mRNAs in vitro by inhibiting initiation and promoting deadenylation. Genes Dev 2007, 21:1975-1982.
3. Ambros V: The functions of animal microRNAs. Nature 2004, 431:350-355.
4. Nakao K, Minobe W, Roden R, et al.: Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997, 100:2362-2370.
5. van Rooij E, Sutherland LB, Qi X, et al.: Control of stressdependent cardiac growth and gene expression by a microRNA. Science 2007, 316:575-579. This landmark paper describes a role for miR-208, embedded within one of the MHC genes, in counterregulation of the two MHC genes. This established a mechanism relating the genetic locus of a miR to its primary function.
6. Callis TE, Pandya K, Seok HY, et al.: MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009, 119:2772-2786.
7. Chien KR, Knowlton KU, Zhu H, Chien S: Regulation of cardiac gene expression during myocardial growth and hypertrophy: Molecular studies of an adaptive physiologic response. FASEB J 1991, 5:3037-3046.
8. Heidecker B, Kasper EK, Wittstein IS, et al.: Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. Circulation 2008, 118:238-246.
9. Margulies KB, Bednarik DP, Dries DL: Genomics, transcriptional profiling, and heart failure. J Am Coll Cardiol 2009, 53:1752-1759.
10. Dorn GW 2nd, Matkovich SJ: Put your chips on transcriptomics. Circulation 2008, 118:216-218.
11. Condorelli G, Latronico MVG, Dorn GW 2nd: MicroRNAs in cardiovascular disease: Putative novel therapeutic targets? Eur Heart J 2010 Jan 29 [Epub ahead of print].
12. van Rooij E, Sutherland LB, Liu N, et al.: A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006, 103:18255-18260.
13. Thum T, Galuppo P, Wolf C, et al.: MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 2007, 116:258-267.
14. Ikeda S, Kong SW, Lu J, et al.: Altered microRNA expression in human heart disease. Physiol Genomics 2007, 31:367-373.
15. Sucharov C, Bristow MR, Port JD: MiRNA expression in the failing human heart: Functional correlates. J Mol Cell Cardiol 2008, 45:185-192.
16. Naga Prasad SV, Duan ZH, Gupta MK, et al.: Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem 2009, 284:27487-27499.
17. Matkovich SJ, Van Booven DJ, Youker KA, et al.: Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009, 119:1263-1271, This is the only study to date comparing mRNA and miR expression profiles in different stages of heart failure. It established greater sensitivity of the miR signature for clinical status.
18. Margulies KB, Matiwala S, Cornejo C, et al.: Mixed messages: Transcription patterns in failing and recovering human myocardium. Circ Res 2005, 96:592-599.
19. Mitchell PS, Parkin RK, Kroh EM, et al.: Circulating micro- RNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518, This paper established that circulating miRs are stable for extended periods of time in blood, and can be accurately measured in a manner that reflects their regulated expression in tissue. This important finding suggests that a blood test may provide the same miR expression signature information as myocardial biopsy.
20. Care A, Catalucci D, Felicetti F, et al.: MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13:613-618, Information in this paper indicates that synthetic miR agonists and antagonists (in the form of a complementary single strand sequence) can be useful to mimic or oppose specific miR effects in the in vivo heart.
21. Liu N, Bezprozvannaya S, Williams AH, et al.: MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008, 22:3242-3254.
22. Bernstein E, Kim SY, Carmell MA, et al.: Dicer is essential for mouse development. Nat Genet 2003, 35:215-217.
23. Chen JF, Murchison EP, Tang R, et al.: Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2008, 105:2111-2116.
24. da Costa Martins PA, Bourajjaj M, Gladka M, et al.: Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008, 118:1567-1576.
25. Rao PK, Toyama Y, Chiang HR, et al.: Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 2009, 105:585-594.
26. Suckau L, Fechner H, Chemaly E, et al.: Long-term cardiactargeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 2009, 119:1241-1252.
27. Zhao Y, Ransom JF, Li A, et al.: Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007, 129:303-317.
28. Lin Z, Murtaza I, Wang K, et al.: MiR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A 2009, 106:12103-12108.
29. van Rooij E, Marshall WS, Olson EN: Toward microRNA-based therapeutics for heart disease: The sense in antisense. Circ Res 2008, 103:919-928.
30. Wang S, Olson EN: AngiomiRs-key regulators of angiogenesis. Curr Opin Genet Dev 2009, 19:205-211.
31. Wang S, Aurora AB, Johnson BA, et al.: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008, 15:261-271.
32. Ren XP, Wu J, Wang X, et al.: MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 2009, 119:2357-2366.
33. Rane S, He M, Sayed D, et al.: Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009, 104:879-886.
34. Thum T, Gross C, Fiedler J, et al.: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
35. van Rooij E, Sutherland LB, Thatcher JE, et al.: Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008, 105:13027-13032.